Premium
Blastic mantle cell lymphoma developing concurrently in a patient with chronic myelogenous leukemia and a review of the literature
Author(s) -
Rodler Eve,
Welborn Jeanna,
Hatcher Sandra,
Unger Katherine,
Larkin Edward,
Gumerlock Paul H.,
Wun Theodore,
Richman Carol
Publication year - 2004
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20025
Subject(s) - medicine , chronic myelogenous leukemia , mantle cell lymphoma , imatinib mesylate , lymphoma , pathology , leukemia , malignancy , lymphocytosis , chronic lymphocytic leukemia , imatinib , oncology , cancer research , myeloid leukemia
Non‐Hodgkin's lymphoma (NHL) occurring as a synchronous malignancy with chronic myelogenous leukemia (CML) is rare. To our knowledge, this is the first case reported of a patient who developed mantle cell lymphoma (MCL) after therapy with imatinib mesylate for CML. After a 3‐year history of CML, the patient developed a lymphocytosis associated with diarrhea, anorexia, and weight loss. Imaging studies revealed abdominal adenopathy and extensive lymphomatous infiltration of the liver, stomach, pancreas, and kidneys. Flow cytometric and cytogenetic studies were consistent with MCL. Fluorescence in situ hybridization (FISH) of the bone marrow revealed a genetically distinct lymphoid neoplasm rather than an extramedullary blast crisis of CML. The development of lung cancer, prostate cancer, CML and MCL in this patient suggests a genetic predisposition, although other factors, including environmental exposures and therapy with imatinib mesylate could have had a contributory or synergistic role in the development of MCL. Am. J. Hematol. 75:231–238, 2004. © 2004 Wiley‐Liss, Inc.